Compare Diastika Biotekindo Tbk. (CHEK) vs UBC Medical Indonesia Tbk. (LABS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diastika Biotekindo Tbk. vs UBC Medical Indonesia Tbk. — how do they compare? Diastika Biotekindo Tbk. trades at Rp126 (market cap 518.28B, 187.3K 24h volume), while UBC Medical Indonesia Tbk. trades at Rp146 (market cap 576.7B, 3.06M 24h volume). The key difference: Diastika Biotekindo Tbk. and UBC Medical Indonesia Tbk. are close in size by market cap, and UBC Medical Indonesia Tbk. is more actively traded (3.06M versus 187.3K). Which is the better fit depends on your goals.
| CHEK | LABS | |
|---|---|---|
Market Cap | 518.28B | 576.7B |
Volume | 187.3K | 3.06M |
Lot | 1.87K | 30.57K |
Turnover | 23.74M | 460.09M |
Average Price | 126.77 | 150.51 |
Value | 23.74M | 460.09M |
Indicative Equilibrium Price | 126 | 147 |
Indicative Equilibrium Volume | 500 | 311 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diastika Biotekindo Tbk.
PT Diastika Biotekindo Tbk. (The Company) was established in Jakarta based on Deed No. 33 dated July 20, 1989 made before Mrs. Sitti Marjami Soepangat, SH. notary in Jakarta. The Company started its commercial activities in years 1986. The parent entity as well as the ultimate parent entity of the Company is PT Optel Investama Mulia.
Read more on CHEK →About UBC Medical Indonesia Tbk.
PT UBC Medical Indonesia (the Company) was established under the framework of Law of the Republic of Indonesia No. 20 year 1994 concerning the Foreign Capital Investment, as amended by Law No. 25 year 2007 concerning the Capital Investment based on Notarial Deed No. 01 dated 4 June 2014 of Novita Puspitarini, S.H., Notary in Jakarta. The Company started its commercial activities in October 2014. The parent entity as well as the ultimate parent entity of the Company is PT Optel Investama Mulia.
Read more on LABS →
